Clinical Trials
12 trialsNCT02465060 2026-05-26
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06897735 2025-11-18
EDDIS-a1
Petrov, Andrey
Phase 1 Not yet recruiting
NCT01553942 2024-11-20
Afatinib With CT and RT for EGFR-Mutant NSCLC
Massachusetts General Hospital
Phase 2 Active not recruiting
NCT02768337 2024-01-31
CamBMT1
Cambridge University Hospitals NHS Foundation Trust
Phase 1/2 Terminated
NCT02716311 2022-08-11
ACE-Lung
Intergroupe Francophone de Cancerologie Thoracique
Phase 2 Completed
NCT02629523 2021-08-03
LiquidLung-A
Chonnam National University Hospital
Phase 2 Completed
NCT01999985 2020-11-27
Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT01466660 2020-04-07
LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung
Boehringer Ingelheim
Phase 2 Completed
NCT02271906 2019-04-30
The ATTAIN Study: A Therapeutic Trial of Afatinib In the Neoadjuvant Setting
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT02145637 2019-03-29
Phase I Study of the Combination of Afatinib and Ruxolitinib in Patients With Treatment-refractory Non-Small Cell Lung Cancer (NSCLC)
Yonsei University
Phase 1 Completed
NCT02625168 2015-12-09
Afatinib vs Erlotinib as 2nd TKI After Failure to 1st TKI and Chemotherapy for Metastatic NSCLC
The University of Hong Kong
Phase 2 Completed
NCT01480141 2013-03-26
A Window of Opportunity Trial of Afatinib In Early Stage Non-Small Cell Lung Cancer (NSCLC)
Medical University of South Carolina
Phase 2 Withdrawn